Select updates are outlined below. Check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bopp.pdf
Version 2.2026 focused on adding comprehensive prostate cancer information and revising the name of the guidelines to encompass prostate cancer. Updates included:
- Recommendations (BRCA2) and considerations (ATM, BRCA1, CHEK2, HOXB13, PALB2, and TP53) for prostate cancer screening which are meant to be annual.
- Adding HOXB13 in gene table, indicating an absolute prostate cancer risk: ~33-60% by age 80, predominantly based on the p.G84E variant. More recently, the X285K variant has been identified in males of African ancestry. Overall, HOXB12 is not associated with aggressive disease, based on the majority of studies to date.
- Among BRCA1/2 carriers, prostate cancer screening may also include a baseline mpMRI by age 50 or 10 years younger than age at prostate cancer in the family, which should be done on clinical trial and in experienced high-volume centers. Moreover, screening should be done through a shared decision-making model, with discussion of potential limitations, including cost, high incidence of benign or indeterminate abnormalities, and uncertainties about the potential benefits
Version 3.2026 encompassed updates to the discussion section.